WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

DOCUMENT MADE AVAILABLE UNDER THE PATENT COOPERATION TREATY (PCT)

International application number:		**PCT/GB2017/050038**
International filing date:		**09 January 2017 (09.01.2017)**
Document type:		**Certified copy of priority document**
Document details:	Country/Office:	**GB**
	Number:	**1600380.8**
	Filing date:	**08 January 2016 (08.01.2016)**
Date of receipt at the International Bureau:		**18 January 2017 (18.01.2017)**

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-*bis*)

34, chemin des Colombettes
1211 Geneva 20, Switzerland

Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as stored electronically on the Patents Electronic Case file System in connection with patent application GB1600380.8 filed on 8th January 2016

The Patents Electronic Case-file System is compliant with British Standard BS10008 - Evidential weight and legal admissibility of information stored electronically and ISO15801 - Electronic imaging – information stored electronically, recommendations for trustworthiness and reliability.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed 

Dated 12th January 2017

Intellectual Property Office

Patents Form 1
Patents Act 1977 *(Rule 12)*

Request for grant of a patent

Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

Application number GB 1600380.8

1.	Your reference	**N406714GB**
2.	Full name, address and postcode of the applicant or of each applicant Patents ADP number *(if you know it)*	**Replimune Limited** **The Magdalen Centre Oxford Science Park** **Robert Robinson Avenue** **Oxford OX4 4GA** **United Kingdom** 11627528001
3.	Title of the invention	**MODIFIED VIRUS**
4.	Name of your agent *(if you have one)* "Address for service" to which all correspondence should be sent. This may be in the European Economic area or Channel Islands (see warning note below) *(including the postcode)* Patents ADP number *(if you know it)*	**J A Kemp** **J A Kemp** **14 South Square** **Gray's Inn** **London WC1R 5JJ** **Greater London** **United Kingdom** 10645901001
5.	Priority declaration: Are you claiming priority from one or more earlier-filed patent applications? If so, please give details of the application(s)	

Country	Application number	Date of filing	PDAS Access Code

6.	Divisionals etc: Is this application a divisional application, or being made following resolution of an entitlement dispute about an earlier application. If so, please give the application number and filing date of the earlier application	Number of earlier UK application	Date of filing *(day / month / year)*
7.	Inventorship: (Inventors must be individuals not companies) Are all the applicants named above also inventors?	**No**	
8.	Are you paying the application fee with this form?	**No**	

9. Accompanying documents: please enter the number of pages of each item accompanying this form.

Continuation sheets of this form

Description:	**22**
Claim(s):	**6**
Abstract:	**1**
Drawing(s):	**2**

If you are not filing a description, please give details of the previous application you are going to rely upon

Country	Application number	Date of filing	PDAS Access Code

10. If you are also filing any of the following, state how many against each item.

Priority documents:	**0**
Statement of inventorship and right to grant of a patent (Patents Form 7):	**0**
Request for search (Patents Form 9A):	**0**
Request for a substantive examination (Patents Form 10):	**0**
Any other documents (please specify):	**Sequence Listing**

11. I/We request the grant of a patent on the basis of this application.

Signature: **Subject: Pamela Tuxworth 23470; Issuer: European Patent Office, European Patent Office CA G2** Date: **08 Jan 2016**

12. Name, e-mail address, telephone, fax and/or mobile number, if any, of a contact point for the applicant

TUXWORTH, Ms. Pamela Mary
Email: mail@jakemp.com
Telephone: +44 20 3077 8600
Fax: +44 20 7430 1000

Warning
After an application for a patent has been filed, the Comptroller will consider whether publication or communication of the invention should be prohibited or restricted under section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you are resident in the United Kingdom and your application contains information which relates to military technology, or would be prejudicial to national security or the safety of the public, section 23 of the Patents Act 1977 prohibits you from applying for a patent abroad without first getting written permission from the Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked. Until such time or until the revocation of any direction, for any such application the address for service referred to at part 4 above must be in the United Kingdom.

Although you may have an address for service in the Channel Islands, any agent instructed to act for you must reside or have a place of business in the European Economic Area or Isle of Man.

MODIFIED VIRUS

Field of the Invention

The invention relates to an oncolytic immunotherapeutic agent and to the use of the oncolytic immunotherapeutic agent in treating cancer.

Background to the Invention

Viruses have a unique ability to enter cells at high efficiency. After entry into cells, viral genes are expressed and the virus replicates. This usually results in the death of the infected cell and the release of the antigenic components of the cell as the cell ruptures as it dies. As a result, virus mediated cell death tends to result in an immune response to these cellular components, including both those derived from the host cell and those encoded by or incorporated into the virus itself. The immune response is also enhanced due to the recognition by the host of so called damage associated molecular patterns (DAMPs) which aid in the activation of the immune response.

Viruses also engage with various mediators of the innate immune response as part of the host response to the recognition of a viral infection through, for example, toll-like receptors, cGAS/STING signalling and the recognition of pathogen associated molecular patterns (PAMPs) resulting in the activation of interferon responses and inflammation which are also immunogenic signals to the host. These immune responses may result in the immunogenic benefit to cancer patients such that immune responses to tumor antigens provide a systemic overall benefit resulting in the treatment of tumors which have not been infected with the virus, including micro-metastatic disease, and providing vaccination against relapse.

The combined direct ('oncolytic') effects of the virus, and immune responses against tumor antigens (including non-self 'neo-antigens', i.e. derived from the particular mutated genes in individual tumors) is termed 'oncolytic immunotherapy'.

Viruses may also be used as delivery vehicles ('vectors') to express heterologous genes inserted into the viral genome in infected cells. These properties make viruses useful for a variety of biotechnology and medical applications. For example, viruses expressing heterologous therapeutic genes may be used for gene therapy. In the context of oncolytic immunotherapy, delivered genes may include those encoding specific tumor antigens, genes intended to induce immune responses or increase the immunogenicity of

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.